Investing.com – Stoke Therapeutics Company (NASDAQ: STOK) Q1 reports beat analyst expectations. with revenue higher than expected numbers According to information published on Monday.
Stoke Therapeutics earnings per share (EPS) were $-0.65 on revenue of $3.27M. Investing.com previously viewed the figure at $-0.71 per share on a $2.86M earnings basis.
Stoke Therapeutics shares were down 1.93% to $8.66 during the day following the earnings news.
In addition to Stoke Therapeutics, there are other companies. in the healthcare sector of the NASDAQ stock market who reported earnings during this month
AbbVie previously reported fourth quarter earnings of $3.6 per share on revenue of $15.12B, compared with expectations of $3.53 and revenue of $15.33B.
Meanwhile, AstraZeneca ADR’s recent performance beat analyst expectations. Fourth-quarter earnings of $0.69 per share and revenue of $11.21B beat analysts’ expectations. Investing.com It expects earnings per share to be around $0.6716 on a $11.25B revenue basis.
Stay up-to-date on company profits through Investing.com earnings calendar
